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Abstract Immunoglobulin (Ig)G antineutrophil cytoplas-
mic autoantibodies are causally associated with necrotizing
vasculitides that are characterized immunopathologically by
little or no deposition of immunoreactants, such as Wegener
granulomatosis, microscopic polyangiitis, Churg–Strauss
angiitis, "renal-limited" vasculitis and a number of drug-
induced vasculitides. Clinical routine testing targets the
antigens myeloperoxidase and proteinase 3. However, in all
of the conditions mentioned, the renal histopathologic
findings are indistinguishable. Churg–Strauss angiitis (char-
acterized by necrotizing vasculitis, granulomatous inflam-
mation and tissue eosinophilia), Wegener granulomatosis
(characterized by necrotizing vasculitis and granulomatous
inflammation) and microscopic polyangiitis (characterized
by necrotizing vasculitis) often present with fever, weight
loss and a multisystem involvement (ear, nose, throat, lung,
eyes, peripheral nerve and heart). Fifty years ago these
conditions were very often fatal within 6 months of
diagnosis. The introduction of corticosteroids and cyclo-
phosphamide has resulted in a dramatic clinical benefit.
Patients who develop treatment-related morbidity can be
switched from cyclophosphamide to azathioprine after
achieving remission. In patients with less severe disease,
methotrexate achieves remission with a success rate similar
to that of cyclophosphamide. Plasma exchange, in associ-
ation with immunosuppression, is likely to be a beneficial
therapy for patients with severe kidney disease or pulmo-
nary hemorrhage.
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Introduction
An aberrant interaction between neutrophils and vascular
endothelial cells underlies the development of necrotizing
vasculitides that are characterized by little or no deposition
of immunoreactants, such as immunoglobulin (Ig)A, IgM,
IgG and complement components. This distinct group of
disorders includes Wegener granulomatosis, microscopic
polyangiitis, Churg–Strauss angiitis and a number of drug-
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induced vasculitides [1–3]. Necrotizing vasculitides in both
children and adults are associated with circulating IgG
antineutrophil cytoplasmic autoantibodies (ANCA) [1–3].
Recent data indicate that IgG ANCA are directly
involved in the pathogenesis of vascular injury: in
susceptible individuals, infections with fimbriated bacteria
trigger Wegener granulomatosis, microscopic polyangiitis,
“renal limited vasculitis” and Churg–Strauss angiitis by
inducing the production of antibodies to a human protein
expressed on neutrophils, the lysosomal membrane protein-
2. These antibodies activate neutrophils which, in turn, may
erode the vasculature [4].
In this review article we focus on the presentation and
the management of children with ANCA-positive vasculit-
ides. The classification criteria for a number of pediatric
vasculitides developed by the European League against
Rheumatism and the Pediatric Rheumatology European
Society will be used [5].
Antineutrophil cytoplasmic autoantibodies testing
The antigens targeted during clinical routine testing of
IgG ANCA are myeloperoxidase and proteinase 3,
which are located in the azurophilic granules of
neutrophils and the peroxidase-positive lysosomes of
monocytes. Two major immunofluorescence patterns
occur (Fig. 1). (1) The perinuclear or “P-ANCA” pattern
results from a staining pattern around the nucleus, with the
antibody responsible for this pattern usually directed
against myeloperoxidase (and only occasionally protein-
ase 3). (2) The cytoplasmic or “C-ANCA” pattern is
characterized by a diffuse staining throughout the cyto-
plasm; in most cases, antibodies directed against protein-
ase 3 cause this pattern, but myeloperoxidase can
occasionally be responsible [6, 7].
In some patients with connective tissue disorders,
chronic inflammatory bowel disease and autoimmune
hepatitis, an atypical ANCA pattern that may be confused
with “P-ANCA” patterns are sometimes observed. “P-
ANCA” are common in patients with cystic fibrosis,
particularly those patients with severe bacterial airway
infections. In this case, they are directed against the
bactericidal permeability increasing protein, a factor of the
innate defense repertoire against Gram-negative bacteria [6, 7].
The indirect immunofluorescence assay, which remains
non-standardized, is sensitive but not highly specific, while
the enzyme-linked immunosorbent assay (ELISA), which is
performed using purified specific antigens, is more specific.
Consequently, the currently recommended approach is to
screen for ANCA using immunofluorescence assays and to
confirm positive results with ELISA in order to determine
the specific antibody [6, 7].
Because of the common difficulty in distinguishing
the P-ANCA pattern of immunofluorescence from that
caused by antinuclear antibodies, individuals with
antinuclear antibodies often have "false-positive" results
based on ANCA testing by immunofluorescence. Rigor-
ous immunofluorescence testing procedures for ANCA
include the use of both ethanol- and formalin-fixed
neutrophil substrates primarily because formalin-fixed
neutrophils prevent the rearrangement of charged cellu-
lar components around the nucleus. The use of both cell
substrates enables antibodies causing a "true" P-ANCA
pattern to be distinguished from those directed against
the nuclear antigens [6, 7].
As stated above, ANCA are associated with many
cases of Wegener granulomatosis, microscopic periarter-
itis, Churg–Strauss angiitis, "renal-limited" vasculitis
and some drug-induced vasculitides (Table 1). Under
these conditions, ANCA have specificities for either
proteinase 3 or myeloperoxidase, but almost never for
both.
Fig. 1 Testing for antineutrophil cytoplasmic autoantibodies (ANCA)
by indirect immunofluorescence using ethanol-fixed neutrophil sub-
strates. The upper panel reveals a diffuse granular cytoplasmic
staining pattern, characteristic of cytoplasmic ANCA (C-ANCA). The
lower panel reveals a homogenous perinuclear staining pattern, which
is characteristic for perinuclear autoantibodies (P-ANCA)
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Wegener granulomatosis
Approximately 90% of patients with active, generalized
Wegener granulomatosis are ANCA-positive (in 80–90% of
these, the antibodies are directed against proteinase 3; in the
remaining patients, the ANCA-positive antibodies are
directed against myeloperoxidase). ANCA-negative
patients with active disease mostly suffer from a limited
form of the disease. Thus, the absence of ANCA clearly
does not exclude the diagnosis of Wegener granulomatosis
[6, 7].
Microscopic polyangiitis (and renal-limited vasculitis)
Approximately 70% of the patients with microscopic
polyangiitis and renal limited vasculitis are ANCA-
positive, with 75–80% having myeloperoxidase-ANCA [6,
7].
Churg–Strauss angiitis
Approximately 25–50% of patients affected with Churg–
Strauss angiitis are ANCA positive, with the percentage being
somewhat higher in those with active, untreated disease. There
is a moderate predilection for myeloperoxidase-ANCA
among those patients with Churg–Strauss angiitis who have
ANCA [6, 7].
ANCA-positive drug-induced vasculitides
Patients with drug-induced ANCA associated vasculitides
mostly have myeloperoxidase-ANCA in very high titers. In
addition, most also have antibodies to elastase or lactofer-
rin. Identical testing (including antibodies to elastase or
lactoferrin) may also be seen in acute-drug-induced
interstitial nephritis [6, 7].
Clinical features
The renal histopathologic findings are indistinguishable in
Wegener Granulomatosis, microscopic polyangiitis and
renal-limited vasculitis (Fig. 2). Furthermore, some children
who present with disease limited to the kidney, i.e. with
renal-limited vasculitis, eventually exhibit extrarenal man-
ifestations of either Wegener granulomatosis or microscopic
polyangiitis. There is also some overlap between Wegener
granulomatosis and microscopic polyangiitis. The distinction
between microscopic polyangiitis and Wegener granuloma-
tosis is critical chiefly because Wegener granulomatosis is
Table 1 Features in pediatric patients with Wegener granulomatosis, microscopic polyangiitis and Churg–Strauss angiitis
Feature Wegener granulomatosis Microscopic polyangiitis Chrurg-Straus angiitis
IgG/ANCA
positivity
90% 70% ≤50%
Antigen Proteinase 3a Myeloperoxidase >
proteinase 3
Myeloperoxidase > proteinase 3
Peripheral
eosinophilia
Rather rare (and mild) - Very often (and severe)
Histology Necrotizing vasculitis–granulomatous inflammation Necrotizing vasculitis–no
granulomatous
inflammation
Necrotizing vasculitis–
granulomatous inflammation–
tissue eosinophilia
Fever,
weight loss
Very often Very often Very often
Ear, nose,
throat
Sinusitis, saddle nose, epistaxis, oral or nasal ulcers, otitis,
conductive hearing loss, subglottic stenosis
Absent or mild Nasal polyps, allergic rhinitis,
conductive hearing loss
Lung Nodules, infiltrates, cavitary lesions, rarely alveolar
hemorrhage
Alveolar hemorrhage Asthma, nonfixed infiltrates, rarely
alveolar hemorrhage
Kidney Segmental necrotizing glomerulonephritis (granulomatous
inflammation rarely seen in biopsy specimens)
Segmental necrotizing
glomerulonephritis
Segmental necrotizing
glomerulonephritis
Eye Conjunctivitis, (epi)scleritis, orbital inflammatory disease,
uveitis
Occasionally (epi)scleritis,
uveitis
Occasionally (epi)scleritis, uveitis
Peripheral
nerve
Occasionally vasculitic neuropathy Often vasculitic neuropathy Often vasculitic neuropathy
Heart Occasionally valvular lesions Rare Often cardiomyopathy, pericardial
effusion or valvular lesions
Ig, Immunoglobulin; ANCA, antineutrophil cytoplasmic autoantibodies
a Very rarely myeloperoxidase
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substantially more likely to relapse after the achievement of
remission and the discontinuation of the drug management.
Wegener granulomatosis
Wegener granulomatosis is a systemic pauci-immune necro-
tizing, predominantly small-vessel vasculitis associated with
granulomatous inflammation [5, 8].
In its “classic form” the condition primarily involves the
(upper or lower) respiratory tract and the kidneys. In
childhood, the main features at presentation include (1) a
female predominance (female-to-male ratio: 4:1), (2) a
disease onset most commonly occurring in adolescence and
(3) an initial multisystemic presentation with constitutional
(fever and weight loss) and respiratory symptoms (Fig. 3)
and renal involvement. Most children seek medical advice
because of respiratory symptoms. Common and uncommon
clinical features in pediatric patients with Wegener gran-
ulomatosis are given in Table 2 [9–13].
In addition to a positive proteinase 3 ANCA testing, the
most common laboratory abnormalities at presentation are a
consistently elevated erythrocyte sedimentation and ane-
mia, which are found in approximately 90–95% of patients.
Less common are altered urinalysis, thrombocytosis, leu-
kocytosis and elevated C-reactive protein, which are found
in approximately 50% of patients [8–13].
The European classification criteria for Wegener gran-
ulomatosis require the diagnosis of three of the following
six features: (1) abnormal urinalysis; (2) nasal sinus
inflammation; (3) subglottic, tracheal or endobronchial
stenosis; (4) abnormal chest imaging; (5) positive ANCA
testing; (6) granulomatous inflammation on biopsy [5].
Microscopic polyangiitis (and renal-limited vasculitis)
Microscopic polyangiitis is a pauci-immune necrotizing small
vessel vasculitis without clinical or pathological evidence of
necrotizing granulomatous disease of the respiratory tract. The
condition predominantly (80%) affects the female gender.
Approximately 90% of the patients with microscopic poly-
angiitis have glomerulonephritis, which is accompanied by a
variety of other organ involvement [5, 14–16]. The distinction
between Wegener granulomatosis and microscopic polyan-
giitis is sometimes difficult to determine [17]. Nasal septal
perforation or saddle-nose deformity or thoracic imaging
showing nodules or nodular infiltrates that have a tendency
to cavitate are usually regarded as typical features of
Wegener granulomatosis. Some patients initially present
with a vasculitis limited to the kidney [18–20]. However,
the great majority of these patients eventually develop
extrarenal manifestations of microscopic polyangiitis (more
rarely Wegener granulomatosis).
No formal classification criteria for the diagnosis of
microscopic polyangiitis in pediatric patients have been
proposed by the European League against Rheumatism and
the Pediatric Rheumatology European Society [5].
Churg–Strauss angiitis
The pathologic features of Churg–Strauss angiitis include
granulomatosis, vasculitis and eosinophilia [21, 22]. This
Fig. 3 In this 14-year-old female adolescent with fever, weight loss
and moderate cough for 2 months, the chest X-ray discloses (arrow) a
nodular lesion in the right upper lobe. The subsequent diagnostic
work-up confirmed the working diagnosis of Wegener granulomatosis.
The possible diagnosis of tuberculosis was considered, and sputum
specimens were submitted to the laboratory for smear and culture
Fig. 2 Characteristic picture of a pauci-immune extracapillary
necrotizing glomerulonephritis. The depicted glomerulus contains a
segmental fibrinoid necrosis, a cellular crescent and some neutrophil
granulocytes (acid fuchsin–Orange G stain). The yellow arrow denotes
the cellular crescent, the red arrow the fibrinoid necrosis
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very rare multisystem disorder sometimes develops in
asthma patients receiving therapy with a leukotriene
antagonist, suggesting that these drugs either cause (or
unmask) this angiitis [23]. No pediatric cases of the
condition have so far been associated with leukotriene
antagonists [24]. A recently performed literature analysis
revealed 33 cases of this vasculitis in individuals ≤18 years
of age [24]. All children had eosinophilia (>1.5 109/L) and
increased total IgE levels. At presentation, most children
had a history of asthma (more than 90%) and sinusitis
(80%). Pulmonary involvement presenting as nonfixed
infiltrates was very common (more than 80%), whereas
pleural effusions were rare (approximately 10%). Other
organs, such as the skin (70%), peripheral nerves (40%) and
the gastrointestinal tract (40%) were also frequently
involved, while the renal and musculoskeletal systems were
conspicuous in only every fifth patient. Cardiac involve-
ment was frequently (40%) seen, presenting as cardiomy-
opathy, pericardial effusions or severe mitral valve
regurgitation.
No classification criteria for the diagnosis of Churg–
Strauss angiitis in pediatric patients have been proposed by
the European League against Rheumatism and the Pediatric
Rheumatology European Society [5]. The presence of four
of the following six criteria for the diagnosis in a patient
with documented vasculitis have been suggested: (1)
asthma; (2) eosinophilia on differential white blood cell
count; (3) neuropathy; (4) migratory or transient pulmonary
opacities detected radiographically; (5) paranasal sinus
abnormality; (6) biopsy containing eosinophils in extravas-
cular areas [21, 22].
Drug-induced ANCA-positive vasculitides
Patients with drug-induced ANCA-positive vasculitides
mostly present with fever, weight loss, joint tenderness
and, in particular, cutaneous vasculitis [25, 26]. However,
the full range of clinical features associated with ANCA,
including glomerulonephritis and alveolar hemorrhage, can
also occur, at least in adults. The implicated agents include
medical drugs employed in the treatment of hyperthyroid-
ism (carbimazole, methimazole, propylthiouracil), tumor
necrosis factor-α antagonists (including infliximab, etaner-
cept and adalimumab), allopurinol, cefotaxime, clozapine,
(di)hydralazine, indomethacin, isoniazid, levamisole [27],
minocycline, penicillamine, phenytoin, procainamide and
rifampicin. The illicit drug cocaine has also been associated
with cutaneous vasculitides. Drug-induced ANCA-positive
vasculitides usually resolve with discontinuation of the
offending drug, but ANCA levels persist even after active
vasculitis has abated.
Management
Laboratory tests
Various laboratory tests are used to monitor disease
activity, including leukocytosis, thrombocytosis, elevated
C-reactive protein and, in particular, erythrocyte sedi-
mentation rate, all of which are relatively nonspecific. In
systemic lupus erythematosus, there is a better correla-
tion between erythrocyte sedimentation rate and disease
activity than between C-reactive protein level and disease
activity. In this condition, C-reactive protein is useful for
Table 2 Clinical features in pediatric patients with Wegener gran-
ulomatosis [9–13]
Clinical features Frequency
Constitutional symptoms +++
Fever +++
Weight loss +++
Ear, nose throat +++
Sinusitis ++
Epistaxis ++
Oral or nasal ulcers ++
Otitis, conductive hearing loss ++
Saddle nose +
Subglottic stenosis +
Pulmonary involvement +++
Alveolar hemorrhage ++
Nodule ++
Non-hemorrhagic alveolar involvement +
Pleural effusion +
Pulmonary embolism +
Renal involvement +++
Glomerulonephritic urinalysis +++
Elevated creatinine ++
Arterial hypertension +
Ocular involvement
Conjunctivitis, scleritis ++ / +++
Orbital inflammatory disease (+)
Joint tenderness or swelling +++
Skin involvement ++
Purpuric lesions (palpable) ++
Urticaria +
Panniculitis +
Vascular involvement ++
Deep vein thrombosis ++
Pulmonary embolism ++
Nervous involvement +
+++, >50%; ++, 25–50%; +, 5–25%; (+), <5%
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distinguishing between a disease flare and an infection:
C-reactive protein usually tends to remain normal or
slightly increased in a flare but is elevated in infection,
while the erythrocyte sedimentation rate is elevated in
both. In ANCA-positive vasculitides, however, there is a
limited role for C-reactive protein to distinguish between
disease flare and infection.
In ANCA-positive vasculitides, especially Wegener
granulomatosis, ANCA titers usually parallel the course of
the vasculitis. In particular, the disappearance of ANCA is
almost always associated with clinical remission, and
patients who maintain negative titers after therapy are at
low risk for relapse. A rise in ANCA after remission is
predictive of subsequent clinical relapse. However, because
of the lack of uniform predictability of clinical relapse,
most physicians do not initiate prophylactic therapy on the
basis of ANCA level alone. Nonetheless, these patients
should be monitored carefully for clinical signs of active
disease [28–31].
Drug management
History
Fifty years ago Wegener granulomatosis, the most common
presentation of ANCA-positive vasculitis, was associated
with a patient survival of approximately 6 months after
diagnosis. The introduction in the 1960s of corticosteroids
only extended survival by 12 months. This changed
radically in the early 1970s with the introduction of
cyclophosphamide (in association with prednisone), which
resulted in a dramatic clinical benefit. However, many
patients developed treatment-related morbidity. It is now
known that patients entering remission following induction
with cyclophosphamide can be switched to azathioprine,
which is less toxic, as maintenance therapy. Furthermore,
methorexate achieves remission with a success rate similar
to that of cyclophosphamide in less severe forms of the
disease [29, 30].
Current recommendations for the drug management
of disease activity
ANCA-positive vasculitides are rather rare in children, who
are very often excluded from randomized controlled trials.
Therefore, the present recommendations are extrapolated
from evidence and expert consensus in adults, including a
very careful systematic review [29] and the 2009 recom-
mendations of the European Vasculitis Study Group [30].
The management of these vasculitides includes (1) the
induction and (2) maintenance of remission, (3) the
treatment of relapses and (4) the management of refractory
disease.
Wegener granulomatosis (or microscopic polyangiitis)
Disease limited to the upper respiratory tract Owing to its
favorable response rates and the favorable adverse-effect
profile, cotrimoxazole in a total dosage of approximately
20 mg/kg twice daily can be used alone or in combination
with prednisone to induce and maintain remission when the
disease is limited to the upper respiratory tract (localized
disease).
Generalized non-organ-threatening disease (= early sys-
temic disease) In patients with a localized (non-renal)
disease with constitutional symptoms or a multifocal
disease with a nonlife- or nonorgan-threatening prognosis,
remission is very often obtained using methotrexate
(0.3 mg/kg body weight per week orally) plus prednisone
1 mg/kg per day (instead of the classical but more toxic
management with cyclophosphamide plus prednisone).
Methotrexate and prednisone are also warranted for the
maintenance of remission (unfortunately there is no
evidence for the cessation of methotrexate maintenance
treatment at 12 months).
Generalized organ-threatening disease (= generalized
disease) In Wegener granulomatosis or microscopic poly-
angiitis presenting with constitutional symptoms and
threatened organ function, cyclophosphamide plus predni-
sone given daily currently remains the gold standard
therapy to induced remission. Oral cyclophosphamide
(2 mg/kg per day) and intravenous pulsed cyclophospha-
mide (15 mg/kg every 2–3 weeks) with the same
corticosteroid regimen are equally effective for remission
induction. The addition of infliximab, a tumor necrosis
factor-α antagonist, accelerates the remission by approxi-
mately 6 weeks, allowing early tapering of the cortico-
steroids with a 40% reduction in the cumulative dose. It is
currently recommended to induce remission with intrave-
nous cyclophosphamide (15 mg/kg every 2 weeks for
6 months) plus oral prednisone (started at 1.0 mg/kg,
tapered to 0.20 mg/kg by 6 months and maintained at this
dose until month 15, when it should be tapered to 0.15
mg/kg maintained for at least 3 more months followed by
local practice).
Both azathioprine and methotrexate are used successful-
ly as maintenance therapy for Wegener’s granulomatosis,
but azathioprine has a better toxicity profile than metho-
trexate. The combination of azathioprine and prednisone
effectively maintains remission (it is assumed that in
remission-maintenance one morning dose of prednisone
given every second day is as effective but less likely to
cause adverse effects than half the dose given every day).
Patients who test negative for ANCA benefit most with this
regimen, while patients positive for ANCA should be
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closely monitored because they have a higher probability of
relapse. When cyclophosphamide is discontinued, azathio-
prine is started at 2.0 mg/kg per day (at 6 months it is
reduced to 1.5 mg/kg per day and maintained for at least 6
more months). Mycophenolate mofetil has also been used
in open label studies for remission maintenance.
Severe renal disease and immediately life-threatening
disease Patients with rapidly progressive kidney disease
or with diffuse alveolar hemorrhage have traditionally
received a greater immunosuppressive load, such as daily
pulses of methylprednisolone and intravenous cyclophos-
phamide (3–4 mg/kg per day) over brief periods. However,
the evidence supporting this practice is scarce. Some
studies suggest that plasma exchange [29–32], in associa-
tion with immunosuppression, is beneficial for patients with
moderate to severe chronic kidney disease or pulmonary
hemorrhage (plasma exchange is supposedly effective
because it removes ANCA).
Refractory disease Various experimental therapies have
recently been used for patients not achieving remission
with the gold standard treatment. For these patients,
intravenous immunoglobulin, which may be effective by
interfering with ANCAs binding to their antigens and by
inhibiting ANCAs-mediated neutrophil activation, the
immunosuppressant mycophenolate mofetil , 15-
deoxyspergualin, infliximab and rituximab, a monoclonal
anti-CD20 IgG1 antibody that induces apoptosis of B
lineage cells have been suggested. Although direct compar-
isons with standard therapies are currently unavailable,
there are several reports of patients with refractory disease
who have achieved a remission using rituximab despite the
failure of standard therapies [33].
Churg–Strauss angiitis
Most studies of Churg–Strauss syndrome treatment have
been performed by the French Vasculitis Study Group.
Treatment can be started with prednisone 1 mg/kg per day,
tapering them when the patient improves. In patients with a
very severe disease score, cyclophosphamide should be
introduced to induce remission, which may be maintained
with another less toxic drug [28–30].
Chronic kidney disease
Chronic kidney disease affects almost all patients with
ANCA-positive vasculitides. As in other kidney diseases,
the progression towards end-stage kidney disease is to a
certain extent due to secondary factors that are unrelated to
the activity of the initial disease, including (1) hypertension
and (2) pathological proteinuria. Considering the conse-
quences of systemic hypertension in chronic kidney
diseases, tight control of blood pressure appears to be
crucial. In chronic kidney disease, blocking the renin–
angiotensin–aldosterone system with converting enzyme
inhibitors or with angiotensin II antagonists is superior to a
more conventional antihypertensive treatment regimen in
preventing progression to end-stage kidney disease. Patho-
logical proteinuria is a further independent mediator of
progressive renal function loss that is positively influenced
by drugs blocking the renin–angiotensin–aldosterone sys-
tem. As a consequence, management with a blocker of the
renin–angiotensin–aldosterone system is advised in ANCA-
positive vasculitides with arterial hypertension or overt
proteinuria [34, 35]. During the second and third trimester
of pregnancy, however, the use of drugs that block the
renin–angiotensin–aldosterone system is strongly cautioned
against [36].
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